
Patients can receive their first and subsequent doses of ZARXIO at no cost
Commercial Co-Pay Program for ZARXIO
The Sandoz One Source Commercial Co-Pay Program for ZARXIO supports eligible,* commercially insured patients with their out-of-pocket co-pay costs for ZARXIO.

The ZARXIO Co-Pay Program in 3 simple steps



In-home injection training
Sandoz offers in-home visits where a nurse trainer can visit the patient at their home to provide instruction for administration of ZARXIO.†

Call 1-844-SANDOZ1 (1-844-726-3691) to request training for your patient.
Additional patient support services
Sandoz One Source provides comprehensive patient support services designed to help simplify and support patient access.

- Benefit investigations
- Prior authorization support
- Appeals support
- Independent foundation information
- Patient Assistance Program
- Reimbursement support
ZARXIO Product Replacement Program
As a supplement to the Sandoz Returns Policy, Sandoz One Source offers a simple product replacement process for spoiled ZARXIO products under the following circumstances‡:
- Product was mishandled, dropped, or broken
- Product was inappropriately stored or refrigerated, or was frozen
- There was an admixture error
- Product was reconstituted but not administered due to an unforeseen patient condition or because the patient missed the appointment
Contact a Sandoz One Source case manager at 1-844-SANDOZ1 (1-844-726-3691) to request replacement product.

Click here for additional ZARXIO resources.
This website provides general information and is not intended to provide reimbursement or legal advice. Furthermore, it is not intended to increase or maximize payment by any payer. Because laws, regulations, and coverage policies are complex and updated frequently, you should check with your local Medicare carrier and payers often or go to www.cms.gov.
Nothing in the information provided shall be construed as a guarantee of Sandoz regarding levels of reimbursement, payment, or charge that reimbursement will be received. The ultimate responsibility for obtaining reimbursement lies with the physician, provider, or patient. Please consult with your counsel or reimbursement specialist for any practice-specific reimbursement or billing questions.
Learn about Ziextenzo (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz1
*Eligibility Requirements: Maximum benefit of $10,000 annually. Prescription must be for an approved indication. This program is not health insurance. This program is for insured patients only; cash-paying or uninsured patients are not eligible. Patients are not eligible if prescription for ZARXIO is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TRICARE, or private indemnity plans that do not cover prescription drugs, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. Co-Pay Program may apply to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. Co-Pay Program may not be combined with any other rebate, coupon, or offer. Co-Pay Program has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.
†Training via video and telephone are also available.
‡Additional conditions apply. Product shall be eligible for replacement only (no credit will be issued). Spoilage applies only to infused or injected Products. Samples are not eligible for spoilage replacement. Replacement is not available if Product has been administered. Sandoz can ship replacement Product only to licensed entities. All spoilage replacement requests are subject to review. If already billed or submitted to insurance, or a co-pay or co-insurance payment was received, replacement is not available. Replacement due to loss of refrigeration is limited to five (5) packs per incident, based on SKU dispensing pack quantity, unless the loss was caused by the failure of a Sandoz-provided refrigerator.
G-CSF=granulocyte colony-stimulating factor.
Reference: 1. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.